Top View
- Focus on Four New Drugs: Xofluza, Aimovig, Ajovy, and Emgality Insulin and Tranexamic Acid Mix-Up
- Aimovig (Erenumab) NOTICE
- Potential for Treatment Benefit of Small Molecule CGRP Receptor
- Erenumab Succeeds in Alleviating Migraine Where Other Treatments Fail
- Aimovig (Erenumab) Was Evaluated for Prophylaxis of Migraine in Two Pivotal Studies Across the Migraine Spectrum in Chronic and Episodic Migraine
- PDL)/Non-Preferred Drug List (NPDL
- Therapeutic Drug Class
- Preventive Migraine Products: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Medical Policy No
- Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study
- American Headache Society 61St Annual Scientific Meeting POSTER PRESENTATIONS Friday, July 12 and Saturday, July 13, 2019
- Ambetter 90-Day-Maintenance Drug List- 2020 -Indiana
- Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- Periop Medication Guidelines
- PDCO Minutes of the 15-18 August 2017 Meeting
- PA Drug Name Generic Name PA Summary Name Epaned Enalapril
- Calcitonin Gene-Related Peptide (CGRP) Antagonist C15443-C
- NYS Medicaid Fee-For-Service Preferred Drug List PREFERRED DRUG LIST – TABLE of CONTENTS I
- Drug Formulary
- CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA (B) (4) and 212728 Rimegepant (B) (4)
- Preferred Drug List
- New Drug Update 2018-19 January 2019
- Package Insert
- Medicare Model Guidelines Draft V8.0 1 of 97
- Monoclonal Antibodies Targeting CGRP: from Clinical Studies to Real-World Evidence—What Do We Know So Far?
- Mrx CLINICAL ALERT
- CGRP Antagonists
- And Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
- New Drug Update 2019: a Formulary Approach and Exciting Drugs in the Pipeline
- (CGRP) Inhibitors – Preventative Migraine Treatment for Employer Group Plans
- WHO Drug Information Vol
- Summary Review
- MI Medicaid Clinical and PA Criteria
- AIMOVIG Safely and Effectively
- Vascular Safety of Erenumab for Migraine Prevention
- Self-Administered Medications List
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Non-Preferred Drug List (NPDL)
- Prior Authorization — Premium
- 761077Orig1s000
- Effects of Monoclonal Antagonist Antibodies on Calcitonin Gene-Related Peptide Receptor Function and Trafficking
- Trends in Medication Management 2017
- Hereditary Angioedema
- Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Poster No
- And Area Drug & Therapeutics Committee
- Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
- 2021 Formulary Kaiser Permanente a TRICARE® Prime Option
- Formulary Changes Update
- Corporate Medical Policy Eptinezumab-Jjmr (Vyepti™) “Notification”
- 212728Orig1s000 SUMMARY REVIEW
- Can Monoclonal Antibodies Against CGRP Offer New Treatment Options for Type 2 Diabetes?
- Bluelink Accord Formulary Updates July 2019
- Anti-CGRP Monoclonal Antibodies: a Breakthrough in the Treatment of Migraine
- Calcitonin Gene Related Peptide (CGRP) Inhibitors
- (Aimovig™), Galcanezumab (Emgality®), Fremanezumab (Ajovy®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO025
- Calcitonin Gene-Related Peptide (Cgrp) & Migraines
- CLINICAL PRIOR AUTHORIZATION (PA) TABLE of CONTENTS Medications Requiring Clinical Prior Authorization (PA) for Kansas Medicaid Are Listed in the Table Below